Monitor for the first patient enrolled announcement and any future Phase IIb top-line data readout, which would be the next binary catalyst for SPRC. The QP release is a necessary but non-value-inflecting step — no trading signal from this update alone.
Price Chart
Executive Summary
SciSparc subsidiary NeuroThera Labs announced completion of manufacturing and QP batch release certification for SCI-110, its Phase IIb Tourette Syndrome drug candidate, enabling shipment to three clinical trial sites. This operational milestone moves the program toward patient enrollment but is a procedural step, not a binary catalyst — no efficacy data or enrollment start date was provided.
Key Facts
- NeuroThera completed manufacturing of SCI-110 investigational product and obtained European QP batch release certification
- Phase IIb TS trial sites at Yale, Hannover Medical School, and Tel Aviv Sourasky Medical Center have completed site initiation activities
- Investigational product shipments to study sites expected in the near term
- SCI-110 is a cannabinoid-based drug combining dronabinol and palmitoylethanolamide (PEA)
- SciSparc owns a majority interest in NeuroThera Labs (TSXV: NTLX)
Financial Impact
No financial figures disclosed; this is a clinical operations update with no revenue or cost data
Risk Factors
- Clinical trial enrollment delays are common and not addressed in this release
- SCI-110 is still in Phase IIb with no efficacy data; failure risk remains high for early-stage CNS candidates
- SciSparc has no marketed products and limited cash runway visibility from this filing
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3386394 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.29 | awaiting T+5 | — | $0.8500 (+34.08%) |
Oct 23, 2026 4d ago | 6-K | $1.09 | awaiting T+5 | — | $0.8500 (−22.02%) |
Oct 22, 2026 5d ago | Press Release | $1.20 | awaiting T+5 | — | $0.8500 (−29.17%) |
Oct 15, 2026 12d ago | 6-K | $2.00 $1.20 | ▲ +40.00% | ▲ +38.99% | $0.8500 (+57.50%) |
Oct 15, 2026 12d ago | 6-K | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $0.8500 (−57.50%) |
Oct 15, 2026 12d ago | Press Release | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $0.8500 (−57.50%) |
Oct 7, 2026 20d ago | 6-K | $4.64 $3.63 | ▼ −21.77% | ▼ −20.79% | $0.8500 (−81.68%) |
Sep 30, 2026 27d ago | 6-K | $4.55 $4.43 | ▲ +2.64% | ▲ +3.94% | $0.8500 (+81.32%) |
Sep 24, 2026 4w ago | 6-K | $5.39 $4.55 | ▼ −15.58% | ▼ −15.17% | $0.8500 (−84.23%) |
Sep 23, 2026 4w ago | Press Release | $5.01 $4.72 | ▼ −5.79% | ▼ −5.11% | $0.8500 (−83.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers